Introduction {#h0.0}
============

*Francisella tularensis*, one of the deadliest respiratory pathogens in existence, is considered a potential biological weapon because it is readily aerosolized and exhibits a high degree of infectivity and lethality in humans. An attenuated live vaccine strain (LVS) has been developed but has not been licensed as a vaccine because of an incomplete understanding of the basis for its attenuated virulence and associated side effects. There has been a widespread research effort aimed at elucidating *Francisella* pathogenesis and identifying components for rational vaccine design. *F. tularensis* is a successful pathogen that can evade and suppress innate immune responses. After intranasal infection of mice, *F. tularensis* initially colonizes the lung, infecting several cell types but failing to stimulate proinflammatory cytokine production for the first 2 to 3 days ([@B1]--[@B5]). This initial delay in inflammation contributes to the ability of *F. tularensis* to replicate in the lung, spread into systemic organs, and cause sepsis leading to the host's death ([@B4]). To suppress the early proinflammatory cytokine response, *F. tularensis* employs a variety of strategies, such as avoiding disclosure of itself to the innate immune system ([@B6], [@B7]).

Lipopolysaccharide (LPS) of *F. tularensis* plays a significant role in evasion of host immune responses ([@B8]--[@B11]). LPS, the major component of Gram-negative bacterial outer membranes ([@B12], [@B13]), itself has three components: (i) lipid A, a glucosamine-based glycolipid; (ii) a core oligosaccharide ketosidically linked to lipid A by an eight-carbon sugar, 3-deoxy-[d]{.smallcaps}-manno-octulosonic acid (Kdo); and (iii) the O-antigen polysaccharide comprising multiple repeating units of a complex tetrasaccharide. The lipid A of many bacterial species such as *Escherichia coli* is a powerful stimulant of Toll-like receptor 4 (TLR4)-mediated innate immune responses. In contrast, *F. tularensis* lipid A triggers no TLR-mediated innate response because of a number of key structural modifications ([@B9]); specifically, despite initial similarity to *E. coli* lipid A, the lipid A precursor of *F. tularensis* undergoes dephosphorylation, deacylation, and carbohydrate incorporation that render the molecule undetectable by the TLR4 receptor. Differences in the length of the fatty acid chain of lipid A (16 to 18 carbons for *F. tularensis* as opposed to 12 to 14 carbons for *E. coli*) further enhance the ability of *F. tularensis* to evade TLR4-mediated innate immunity. These modifications contribute to bacterial virulence ([@B8], [@B10]).

A novel LPS-modifying two-component KdhAB Kdo hydrolase enzyme complex has recently been identified in *F. tularensis* ([@B14], [@B15]). A core LPS precursor containing two Kdo residues is first synthesized. One Kdo in the backbone of the core polysaccharide is ketosidically linked to lipid A and glycosidically linked to the remainder of the core polysaccharide, and the second Kdo residue is glycosidically attached as a side chain. KdhAB removes the side chain Kdo, leaving an LPS molecule containing only one Kdo residue ([Fig. 1](#fig1){ref-type="fig"}) ([@B14]--[@B16]). The KdhAB Kdo hydrolase is a two-component enzyme composed of a sialidase-like protein (the catalytic subunit) and a small inner membrane protein (perhaps a membrane-anchoring subunit) ([@B15]). This novel enzyme complex has been reported in two other pathogens, *Helicobacter pylori* and *Legionella pneumophila* ([@B14], [@B17], [@B18]). Its biological significance---in particular, its role in pathogenicity---has not yet been investigated. Here, we show that the *F. tularensis* Δ*kdhAB* LVS mutant is attenuated in a mouse model of infection and stimulates---in a TLR2-dependent manner---a stronger proinflammatory cytokine response than the parental LVS. Furthermore, immunization of mice with the Δ*kdhAB* mutant provides significant protection against fully virulent *F. tularensis* type A strain Schu S4.

![LPSs from *F. tularensis* LVS and Δ*kdhAB* mutant strain differ from each other by a side chain Kdo. The structure of core oligosaccharide synthesized by LVS ([@B55]) and the proposed structure of core oligosaccharide synthesized by the Δ*kdhAB* mutant, as determined by HPAEC ([@B14]), are shown.](mbo0011314390001){#fig1}

RESULTS {#h1}
=======

The *F*. *tularensis* LVS Δ*kdhAB* mutant is attenuated in mice. {#h1.1}
----------------------------------------------------------------

To fully evaluate the importance of the KdhAB Kdo hydrolase in the virulence of *F. tularensis* LVS, *kdhA* and *kdhB* genes were deleted by homologous recombination in an LVS background, giving rise to the Δ*kdhAB* mutant. Previously described analysis by high-performance anion-exchange chromatography (HPAEC) ([@B14]) confirmed that, unlike the LPS of parental LVS, which has a single Kdo residue, the LPS of the Δ*kdhAB* mutant has two Kdo residues ([Fig. 1](#fig1){ref-type="fig"}; see Table S1 in the supplemental material).

To evaluate the role of Kdo hydrolase activity in *F. tularensis* virulence, we infected BALB/cByJ mice with graded doses of LVS or the Δ*kdhAB* mutant via the intranasal route. All mice challenged with 10^3^ CFU of LVS succumbed to the infection within 9 days ([Fig. 2A](#fig2){ref-type="fig"}). In contrast, all mice challenged with a similar dose of the Δ*kdhAB* mutant survived ([Fig. 2A](#fig2){ref-type="fig"}). At a dose of 10^5^ CFU of the Δ*kdhAB* mutant, 17% of the infected mice survived ([Fig. 2A](#fig2){ref-type="fig"}).

![The virulence of the *F. tularensis* LVS Δ*kdhAB* mutant strain is attenuated in mice. (A) Survival of mice after *F. tularensis* intranasal challenge. BALB/cByJ mice (*n* = 6) were challenged intranasally with LVS (10^3^ CFU) or Δ*kdhAB* bacteria (10^3^, 10^4^, or 10^5^ CFU). (B) Bacterial burden in lung, spleen, liver, and blood of mice 6 days after infection. BALB/cByJ mice (*n* = 3) were challenged intranasally with LVS bacteria (10^3^ CFU) or Δ*kdhAB* bacteria (10^3^ CFU).](mbo0011314390002){#fig2}

The observed phenotypes in the Δ*kdhAB* mutant were successfully complemented with the p*kdhAB* plasmid carrying the *kdhA* and *kdhB* genes. LPS analysis showed that the complemented strain had only a single Kdo residue in its core LPS (see Table S1 in the supplemental material). In addition, complementation of Δ*kdhAB* restored virulence to the wild-type (WT) level. The survival rates of BALB/cByJ mice (10 mice in each group) 28 days after an intranasal challenge with 5 × 10^3^ *F. tularensis* LVS or a Δ*kdhAB* mutant harboring either a vector control (pFNLTP6) or a plasmid carrying *kdhAB* genes (p*kdhAB*) were as follows: 0% for mice infected with LVS, 100% for mice infected with the Δ*kdhAB* mutant carrying pFNLTP6, and 20% for mice infected with the Δ*kdhAB* mutant carrying p*kdhAB*. These data indicate that Kdo hydrolase activity is important for the virulence of *F. tularensis* LVS.

We also examined the ability of the Δ*kdhAB* mutant to colonize the lung and to disseminate into other organs after intranasal challenge of mice. Six days after infection with 10^3^ bacteria, both parental LVS and its Δ*kdhAB* mutant had reached a similar level of colonization in the lungs, with counts of 3 × 10^6^ CFU/g and 10^7^ CFU/g, respectively ([Fig. 2B](#fig2){ref-type="fig"}). However, the numbers of Δ*kdhAB* mutant bacteria in spleen, liver, and blood were 1.5 to 3 logarithmic units lower than the numbers of LVS bacteria ([Fig. 2B](#fig2){ref-type="fig"}) (Student's *t* test, *P* \< 0.05). Overall, these results indicate that the Δ*kdhAB* mutant is deficient in its ability to disseminate systemically.

To determine whether the observed defect in dissemination is related to bacterial growth kinetics, growth rates were compared under different conditions. There was no difference in growth between LVS and the Δ*kdhAB* mutant when bacteria were cultured in broth medium or in J774A.1 macrophage-like and MH-S alveolar macrophage-like cell lines (see Fig. S1A and S1B in the supplemental material). Moreover, the Δ*kdhAB* mutant was not sensitive to complement-mediated killing (Fig. S1C). Therefore, the defect of the Δ*kdhAB* mutant in dissemination to systemic organs was not due to a growth defect or to serum sensitivity.

The cytokine response to the *F*. *tularensis* LVS Δ*kdhAB* mutant is enhanced. {#h1.2}
-------------------------------------------------------------------------------

Within the first day after infection, mutants of *F. tularensis* that cannot modify their lipid A elicit a stronger proinflammatory response than parental LVS did ([@B8], [@B19]). Since the KdhAB hydrolase is involved in the modification of the LPS core oligosaccharide but not in the modification of lipid A, we compared the proinflammatory responses to LVS and the Δ*kdhAB* mutant. To this end, mice were challenged intranasally with 10^3^ CFU of either LVS or the Δ*kdhAB* mutant, and the levels of tumor necrosis factor alpha (TNF-α) and interleukin-1β (IL-1β) in samples of bronchoalveolar lavage (BAL) fluid were determined in an enzyme-linked immunosorbent assay (ELISA). Consistent with previous reports ([@B6]), the levels of TNF-α and IL-1β in BAL fluid 24 h after inoculation of LVS bacteria were not different from those in control mice given phosphate-buffered saline (PBS) ([Fig. 3A](#fig3){ref-type="fig"}, left panel). In contrast, the levels of TNF-α and IL-1β were significantly higher (\~2-fold) in mice infected by the Δ*kdhAB* mutant than in mice infected by LVS or control mice given PBS ([Fig. 3A](#fig3){ref-type="fig"}, left panel). The stronger proinflammatory response was not due to differences in bacterial burden, as the numbers of Δ*kdhAB* and LVS bacteria in the lungs were similar ([Fig. 3A](#fig3){ref-type="fig"}, right panel). Therefore, in contrast to LVS, the Δ*kdhAB* mutant elicited an early proinflammatory response that was detected 24 h after infection.

![Enhanced proinflammatory cytokine response to the *F. tularensis* LVS Δ*kdhAB* mutant strain. (A) BALB/cByJ mice (*n* = 3) were challenged intranasally with LVS bacteria (10^3^ CFU), Δ*kdhAB* bacteria (10^3^ CFU), or PBS (control). BAL fluid was collected 24 h after infection, and the levels of TNF-α and IL-1β were measured by ELISA (left panel). The bacterial burden in lung was measured 24 h after infection (right panel). (B) Levels of TNF-α and IL-1β released by *ex vivo* BMMs after stimulation with LVS or Δ*kdhAB* bacteria (MOI of 10, 20, or 50). Culture supernatants were analyzed by ELISA 24 h after infection. (C) TNF-α and IL-1β gene expression in BMMs infected with LVS or Δ*kdhAB* bacteria (MOI of 10). Gene expression was measured by real-time PCR, normalized with RP II gene expression, and reported as relative expression compared with that in uninfected macrophages. All data are presented as mean plus SD (error bars) values (*n* = 3).](mbo0011314390003){#fig3}

To test whether the *in vivo* cytokine response also differs in *ex vivo* macrophages, bone marrow-derived macrophages (BMMs) from C57BL/6J mice were infected at different multiplicities of infection (MOIs) with either LVS or the Δ*kdhAB* mutant. Supernatants were collected after 24 h, and secretion of TNF-α and IL-1β was measured by ELISA. At all MOIs tested, TNF-α secretion by BMMs stimulated by the Δ*kdhAB* mutant was higher by a factor of at least 2 than that by BMMs stimulated by LVS ([Fig. 3B](#fig3){ref-type="fig"}, left panel). Results were similar for IL-1β secretion ([Fig. 3B](#fig3){ref-type="fig"}, right panel). Consistent with the cytokine secretion profile, the expression of TNF-α and IL-1β genes was higher in Δ*kdhAB* mutant-stimulated BMMs than in LVS-stimulated BMMs ([Fig. 3C](#fig3){ref-type="fig"}).

The *F*. *tularensis* LVS Δ*kdhAB* mutant activates the TLR2 signaling pathway. {#h1.3}
-------------------------------------------------------------------------------

To investigate the basis for the enhanced innate immune response to the Δ*kdhAB* mutant, we assessed the responses of murine macrophage-like cell lines in which various TLR signaling pathways were inactivated. Cells were infected with either LVS or the Δ*kdhAB* mutant at an MOI of 100 and lysed 24 h later for measurement of IL-1β. Cell activation was calculated as the IL-1β ratio in infected cells versus uninfected cells. LVS bacteria elicited a proinflammatory response in WT, Unc93B^−/−^, and TLR4^−/−^ cells, but not in MyD88^−/−^ or TLR2^−/−^ cells ([Fig. 4A](#fig4){ref-type="fig"}). These data are in agreement with previous reports that the innate immune response to LVS is mediated through TLR2 signaling ([@B3], [@B20]). Interestingly, the Δ*kdhAB* mutant showed a similar pattern of activation, a result indicating that TLR2---but not TLR3, -4, -7, or -9---mediates the innate immune response to Δ*kdhAB* mutant bacteria. Moreover, the proinflammatory response was significantly greater in Δ*kdhAB* mutant-infected cells than in LVS-infected cells ([Fig. 4A](#fig4){ref-type="fig"}). Control experiments confirmed that WT cells and knockout cells for Unc93B (required for TLR3, TLR7, and TLR9 signaling), MyD88, TLR4, and TLR2 responded to various TLR agonists as expected (data not shown).

![Bacteria of the *F. tularensis* LVS Δ*kdhAB* mutant strain activate NF-κB through the TLR2 signaling pathway. (A) Macrophage-like cell lines were stimulated with LVS or Δ*kdhAB* bacteria for 2 h (MOI = 100). The IL-1β level in cell lysates was assessed by ELISA. Measurements were expressed as fold induction in infected versus uninfected cells (mean plus SD; *n* = 3). (B) HEK293 cells stably expressing TLR2 or TLR4/MD2 were transiently transfected with an NF-κB luciferase reporter plasmid and stimulated for 24 h with LVS or Δ*kdhAB* bacteria (MOI = 20) or with Pam~3~CSK (1 µg/ml) or *E. coli* LPS (100 ng/ml) as positive controls. Purified LPSs from LVS or Δ*kdhAB* bacteria (5 µg/ml) were tested in a mixture with soluble CD14 recombinant protein (5 µg/ml). The data are reported as relative luciferase units and represent fold induction of luciferase activity in the cell lysate compared with that in unstimulated cells (mean plus SD; *n* = 3).](mbo0011314390004){#fig4}

To assess whether Δ*kdhAB* mutant-mediated enhancement of the proinflammatory cytokine response is likely to be due to an increase in nuclear factor κB (NF-κB) activation, we used HEK293 cells expressing TLR2 (HEK-TLR2) or TLR4 and MD2 (HEK-TLR4/MD2). The stable cell lines were transiently transfected with the reporter plasmid pNFκB-luc, which expresses a firefly luciferase gene under control of an NF-κB promoter, and were incubated with LVS or Δ*kdhAB* organisms. Reporter activity in HEK-TLR4/MD2 cells incubated with bacteria of either strain did not differ ([Fig. 4B](#fig4){ref-type="fig"}). On the other hand, reporter activity increased slightly but significantly in HEK-TLR2 cells stimulated with the Δ*kdhAB* mutant over that in HEK-TLR2 cells stimulated with LVS (*P* \< 0.05) ([Fig. 4B](#fig4){ref-type="fig"}). Control experiments using *E. coli* LPS and Pam~3~CSK, known TLR4 and TLR2 antagonists, respectively, showed high NF-κB reporter activity as expected ([Fig. 4B](#fig4){ref-type="fig"}).

Mechanistic basis for activation of TLR2 by the *ΔkdhAB* mutant. {#h1.4}
----------------------------------------------------------------

One possible explanation for the increase in TLR2-mediated NF-κB activity is that, unlike WT LVS LPS, the mutant LPS produced by the Δ*kdhAB* mutant is a TLR2 agonist ([@B9]). To test this hypothesis, we assessed purified LPS preparations from each strain for their ability to activate NF-κB in HEK-TLR2 cells. LPS from LVS and the Δ*kdhAB* mutant showed similar levels of NF-κB reporter activity, which was also similar to that elicited by whole LVS organisms ([Fig. 4B](#fig4){ref-type="fig"}). Additionally, BMMs did not respond to LPS from either LVS or the ∆*kdhAB* mutant by secretion of TNF-α and IL-1β when the purified LPS was tested at concentrations of 50, 250, 1,250, and 10,000 ng/ml (see Fig. S2 in the supplemental material). Taken together, these results show that the Δ*kdhAB* mutant elicits stronger NF-κB activation in a TLR2-dependent manner, with a consequently greater proinflammatory response. However, the greater proinflammatory response induced by the mutant LPS probably is not due to activation of TLR2 by the mutant LPS *per se*, as the LPS of the Δ*kdhAB* mutant alone does not trigger TLR2 signaling *in vitro*.

To further investigate the mechanism for enhanced TLR2 signaling by the ∆*kdhAB* mutant, we evaluated bacterial membrane integrity. A leaky cell membrane caused by ∆*kdhAB* mutation would potentially release TLR2 ligands into the culture supernatant to be detected by host cells. Thus, the growth behaviors of LVS and the ∆*kdhAB* mutant were tested in the presence of SDS and EDTA, agents that inhibit growth of bacterial cells with defective outer membranes. The similar growth characteristics of the two strains ([Fig. 5A](#fig5){ref-type="fig"}) strongly supported the notion that the ∆*kdhAB* mutation does not compromise cell membrane integrity. In an alternative approach, we tested the filtered supernatants of LVS or Δ*kdhAB* cultures for their ability to activate BMMs *in vitro*. The culture supernatants were concentrated by Centricon filter devices and incubated with BMMs for 24 h. Macrophage activation was measured by the release of TNF-α and IL-6. While the addition of LPS or PAM~3~CSK (as positive controls) to the BMMs did result in significant activation of the cells, little activation was seen after the addition of the LVS- or Δ*kdhAB* mutant*-*conditioned media (see Fig. S3 in the supplemental material). The similarly low levels of TNF-α and IL-6 for both LVS and ∆*kdhAB* organisms suggested that there is no leakage of potential TLR2 ligands due to the ∆*kdhAB* mutation.

![Mutation in *kdhAB* leads to enhanced accessibility of the bacterial surface. (A) Investigation of the leaky-membrane phenotype. Mid-logarithmic-phase cultures were spread onto CHAH plates, and a 10-µl volume of SDS (20, 10, and 5%) or EDTA (500, 250 and 125 mM) was spotted onto filter discs. Images were captured after 48 h of bacterial growth. Black arrows indicate zone of inhibition around 6-mm filter discs. (B) *F. tularensis* LVS and ∆*kdhAB* and ∆*wbtA* mutant strains were tested for binding of mouse anti-FopA antibodies to their surface FopA proteins in an antigen accessibility assay. Bacteria---along with surface-bound FopA antibodies---were lysed, and proteins were resolved by 5 to 20% SDS-PAGE. Bound FopA antibodies were detected as IgG heavy chain (HC) and IgG light chain (LC). Total FopA and bacterioferritin (Bfr) protein levels are shown as protein loading controls.](mbo0011314390005){#fig5}

Unable to detect a leaky-membrane phenotype, we next investigated changes in bacterial LPS and cell-surface protein availability. It has been proposed that fully formed LPS on the bacterial surface plays a vital role in preventing the binding of serum complement, antibodies, and receptors of the innate immune system ([@B21]--[@B24]). Toward this end, the analysis of total LPS level and a characteristic LPS banding pattern showed no difference between LVS and the ∆*kdhAB* mutant ([Fig. 6A](#fig6){ref-type="fig"}). Additionally, matrix-assisted laser desorption ionization−time of flight (MALDI-TOF) analysis of lipid A indicated that LVS and the ∆*kdhAB* mutant have similar lipid A mass values ([Fig. 6B](#fig6){ref-type="fig"}). Although the ∆*kdhAB* mutation does not affect the total LPS level or the characteristic banding pattern of LPS, we thought it is possible that the additional Kdo---a negatively charged sugar---in the ∆*kdhAB* mutant alters the conformation of LPS molecules, thereby making other surface constituents more accessible to TLR2 receptors. To test this hypothesis, we evaluated the binding of FopA antibodies to the FopA surface protein *in vitro*. Live bacteria were incubated with mouse antibodies to FopA, and surface-bound antibodies were analyzed by Western blotting. Consistent with a previous study ([@B24]), fully formed LPS significantly reduced the binding of antibodies to the LVS bacterial surface, whereas ∆*wbtA* mutant LPS, which is devoid of O polysaccharide, did not ([Fig. 5B](#fig5){ref-type="fig"}). Strikingly, substantial binding of FopA antibodies to the ∆*kdhAB* mutant bacterial surface was found, and this result suggested that a TLR2 ligand present on the bacterial cell surface would be potentially exposed for detection by host immune-cell TLR2 receptors. The accessibility of surface proteins might well explain the enhanced TLR2 signaling activity caused by the ∆*kdhAB* mutation.

![The *F. tularensis* Δ*kdhAB* mutant strain is not altered in the biosynthesis of O antigen or lipid A. (A) SDS-PAGE analysis of *F. tularensis* LVS and Δ*kdhAB* mutant outer membranes. LPS was visualized by zinc staining. (B) Negative-ion MALDI-TOF analysis of lipid A from LVS and Δ*kdhAB* bacteria.](mbo0011314390006){#fig6}

Biological impact of TLR2 activation by the *ΔkdhAB* mutant. {#h1.5}
------------------------------------------------------------

We next addressed the biological importance of the TLR2-mediated response to Δ*kdhAB* bacteria in a mouse infection model. WT C57BL/6, TLR2^−/−^, and TLR4^−/−^ mice were infected with various doses of the Δ*kdhAB* mutant via the intranasal route and monitored for survival. Most strikingly, at a dose of 10^4^ CFU, all WT and TLR4^−/−^ mice survived, while no TLR2^−/−^ mice survived ([Table 1](#tab1){ref-type="table"}). The results suggest that TLR2-mediated responses play a significant role in the survival of mice infected with the *F. tularensis* Δ*kdhAB* mutant strain. Thus, the association of KdhAB Kdo hydrolase with enhanced TLR2-mediated inflammation points to a critical role for this enzyme complex in the virulence of LVS.

###### 

Survival of WT C57BL/6, TLR2 ^−/−^, and TLR4^−/−^ mice 21 days after an intranasal challenge with *F. tularensis* Δ*kdhAB* mutant

  -----------------------------------------------------
  Challenge\   Survival rate (%) of mice:         
  dose (CFU)                                      
  ------------ ---------------------------- ----- -----
  10^2^        100                          100   100

  10^3^        100                          40    100

  10^4^        100                          0     100
  -----------------------------------------------------

Immunization with *F*. *tularensis* LVS Δ*kdhAB* mutant protects against the highly virulent *F*. *tularensis* Schu S4 strain. {#h1.6}
------------------------------------------------------------------------------------------------------------------------------

Immunization with LVS is protective against the fully virulent *F. tularensis* type A strain Schu S4 in a mouse model of infection, and this protection involves TLR2-dependent innate immunity ([@B25]--[@B27]). However, even in low numbers, LVS retains significant virulence in mice. Our findings that the Δ*kdhAB* mutant is further attenuated and elicits enhanced TLR2 signaling led us to investigate the protective capacity of this mutant strain as a live cell vaccine. To this end, BALB/cByJ mice were immunized with three intranasal doses of LVS, the Δ*kdhAB* mutant, or (as a control) PBS. Four weeks after the last dose, the mice were challenged via the intranasal route with either LVS at a dose of 10^4^ CFU (10 × LD~50~) or the Schu S4 strain at a dose of 10 CFU (10 × LD~50~). All mice that had been immunized with LVS survived LVS challenge, whereas all control mice that had received PBS succumbed within 9 days ([Fig. 7A](#fig7){ref-type="fig"}). The Δ*kdhAB* mutant was also fully protective against LVS challenge ([Fig. 7A](#fig7){ref-type="fig"}). Furthermore, as expected, LVS-immunized mice survived the fully virulent Schu S4 challenge, while all PBS-treated control mice succumbed within 7 days ([Fig. 7B](#fig7){ref-type="fig"}). Strikingly, mice immunized with the Δ*kdhAB* mutant were well protected; 90% of these mice survived an otherwise lethal challenge with Schu S4. Histologic examination of the livers from infected mice revealed that Δ*kdhAB* mutant-immunized mice had much less tissue necrosis after challenge with Schu S4 ([Fig. 7C](#fig7){ref-type="fig"}) than did PBS-treated control mice. The protection conferred by the Δ*kdhAB* mutant was also reflected by lower bacterial loads in the livers, spleens, and lungs from mutant-immunized mice ([Fig. 7D](#fig7){ref-type="fig"}) than in these tissues from PBS-treated control mice. The Schu S4 bacterial loads in organs were similar in LVS- and Δ*kdhAB* mutant-immunized mice. Finally, the levels of *Francisella*-speciﬁc IgG antibody were slightly higher in the sera of Δ*kdhAB* mutant-immunized mice compared to LVS-immunized mice (Fig. 7E).

![Bacteria of the *F. tularensis* LVS Δ*kdhAB* mutant strain elicit protective immunity against *F. tularensis* LVS and type A strain Schu S4. (A and B) Groups of BALB/cByJ mice (10 mice in each group) were immunized intranasally with 3 doses of LVS or ∆*kdhAB* bacteria; 28 days after the last dose, the mice were challenged intranasally with either 10^4^ CFU of LVS (10 × LD~50~) (A) or 10 CFU of strain Schu S4 (10 × LD~50~) (B). (C) Hematoxylin and eosin (H&E) staining of liver tissue on day 5 after Schu S4 challenge. The black arrowhead indicates extensive tissue necrosis (10×). (D) Bacterial burden in lung, spleen, and liver of mice 5 days after Schu S4 challenge (mean plus SD; *n* = 3). (E) Titers of serum antibody to *F. tularensis* LPS were determined by ELISA. Sera from LVS-immunized, Δ*kdhAB* mutant-immunized, and unimmunized control mice were collected on the day before challenge. ELISA was performed as described in Materials and Methods.](mbo0011314390007){#fig7}

DISCUSSION {#h2}
==========

Evasion of innate immunity is a key virulence factor for a number of pathogens, including *F. tularensis* ([@B6], [@B7]). To avoid detection by pattern recognition receptors such as TLRs, *F. tularensis* modifies its lipid A through the action of enzymes such as 4′-phosphatase, galactosamine transferase, and mannosyl transferase ([@B8], [@B10]). A novel LPS modification was hypothesized in *F. tularensis* and *H. pylori*: the removal of side chain Kdo from Kdo~2~-lipid A precursors by a Kdo hydrolase ([@B16], [@B17]). Such a modification was recently confirmed, and the genes coding for a two-component Kdo hydrolase were identified in *F. tularensis* and *H. pylori* ([@B14], [@B15], [@B17], [@B18]). The biological significance of the Kdo hydrolase, which is also expressed by *L. pneumophila* ([@B14]), remained to be addressed. By screening an *F. tularensis* subsp. *novicida* transposon mutant library, Weiss and colleagues showed that a *kdhB* transposon mutant was attenuated in mice, but no further characterization has been reported ([@B28]). Here we demonstrate that the two-component Kdo hydrolase KdhAB is important in the pathogenicity of *F. tularensis* LVS bacteria and in the organism's avoidance of the TLR2-mediated immune response. We further show that a Kdo hydrolase-deficient mutant is protective against the fully virulent *F. tularensis* type A strain Schu S4. Such protective capacity is obviously a key feature to be hoped for in an effective vaccine strain.

The Δ*kdhAB* deletion mutant, unable to remove side chain Kdo from its LPS ([Fig. 1](#fig1){ref-type="fig"}), was impaired in its ability to kill mice after intranasal challenge ([Fig. 2](#fig2){ref-type="fig"}). This attenuation was not due to a growth defect or to sensitivity to complement-mediated killing. In *H. pylori*, Kdo hydrolase inactivation has downstream effects on subsequent steps in LPS biosynthesis, reducing the efficiency of lipid A modification enzymes 4′-phosphatase and 3′-*O*-deacylase and the amount of fully extended O antigen ([@B17]). Both 4′-phosphatase and O antigen are required for full virulence of *F. tularensis* in mice ([@B10], [@B19], [@B29]). However, Kdo hydrolase inactivation in *F. tularensis* LVS did not affect lipid A or O-antigen biosynthesis ([Fig. 6](#fig6){ref-type="fig"}). Therefore, virulence attenuation was not related to a defect in 4′-phosphatase activity or O-antigen assembly.

The avoidance of the TLR response by modifications in lipid A structure has been described in a number of pathogens, including members of the genera *Salmonella*, *Yersinia*, *Pseudomonas*, and *Francisella* ([@B8], [@B10], [@B30]--[@B32]). These modifications include lipid A deacylation, dephosphorylation, and glycosylation. We thus hypothesized that *F. tularensis* removes side chain Kdo from LPS core oligosaccharide to avoid the triggering of innate immunity. In agreement with this hypothesis, the Δ*kdhAB* mutant stimulated a stronger TLR2-mediated proinflammatory response in macrophage monolayers than the parental LVS did ([Fig. 3 and 4](#fig3 fig4){ref-type="fig"}). *In vivo*, Δ*kdhAB* bacteria induced a proinflammatory response in the lungs 24 h after intranasal challenge, while LVS bacteria did not ([Fig. 3A](#fig3){ref-type="fig"}, left panel). Attenuation of the virulence of Δ*kdhAB* bacteria may be related to this early innate immune response. Indeed, several studies have shown that eliciting an early inflammatory response in mice by priming the animals with an agonist of TLR3, TLR4, or TLR9 enhances survival to *F. tularensis* infection and decreases organ bacterial burdens ([@B33]--[@B35]).

Recent studies have indicated that Kdo residues contribute to proinflammatory responses to LPS ([@B36]--[@B38]). Therefore, the presence of a side chain Kdo in the Δ*kdhAB* mutant, with direct recognition of this modified LPS by the TLR2 signaling pathway, has emerged as a potential mechanism for the observed phenotype. However, our *in vitro* studies suggest that this is not the case, as purified LPSs from the Δ*kdhAB* mutant and LVS elicit similarly weak NF-κB activation ([Fig. 4B](#fig4){ref-type="fig"}). Another possible explanation is that the structural alteration of LPS exposes one or more TLR2 ligands present on the bacterial surface. The electrostatic charge of LPS is important for the folding of certain outer membrane proteins ([@B39]--[@B42]), and Kdo---as a negatively charged sugar---contributes to the overall charge of LPS. Thus, the presence of an additional Kdo residue in Δ*kdhAB* mutant LPS may alter the conformation of the outer membrane, exposing TLR2 ligands such as lipoproteins ([@B43]). In support of this idea, we showed that FopA surface protein is more accessible to antibodies in the Δ*kdhAB* mutant than in parental LVS ([Fig. 5B](#fig5){ref-type="fig"}).

LVS is an attenuated *F. tularensis* subsp. *holarctica* strain (type B) that was empirically derived in the former Soviet Union and developed as a live attenuated vaccine against the highly virulent *F. tularensis*. However, the LVS-based vaccine remains unlicensed in the United States and several other nations for several reasons, including the following: (i) an incomplete understanding of the genetic basis for its attenuation; (ii) untoward reactions; and (iii) concerns about possible reversion back to the virulent form. The mechanisms of LVS-mediated protection against tularemia involve TLR2-dependent innate immunity ([@B25]--[@B27]). Therefore, an LVS mutant that exhibits attenuated virulence in mice and more strongly elicits activation of TLR2 signaling might prove to be a safer and more effective vaccine candidate than the original LVS. Here we show that the Δ*kdhAB* LVS mutant may be such a vaccine candidate: its virulence is attenuated, its ability to activate TLR2 is enhanced, and its protective efficacy against *F. tularensis* type A strain Schu S4 is similar to that of LVS. Mutants unable to modify lipid A by carbohydrate incorporation were attenuated in mice, activated proinflammatory responses, and were protective against *F. tularensis* subsp. *novicida* ([@B8]). However, protection against the highly virulent *F. tularensis* type A strain Schu S4 has not been investigated. Few previously assessed mutants have been shown to induce protective immunity against type A strains (for a review, see reference 44). These mutants have had deletions in genes including *FTT1103*, *FTT0918*, *sodB*, *wzy*, and *ggt* ([@B45], [@B46]). We report a new mutation that is relevant for tularemia vaccine design.

Herein we demonstrate that the two-component Kdo hydrolase KdhAB is involved in the virulence of *F. tularensis* LVS. A Δ*kdhAB* mutant is attenuated in mice, elicits a stronger proinflammatory cytokine response in a TLR2-dependent manner, and induces protective immunity against the highly virulent Schu S4 strain of *F. tularensis*. Our data suggest that a novel LPS modification---the removal of side chain Kdo---is important in the evasion of innate immunity by *F. tularensis*. Kdo hydrolase is also produced by two other pathogens, *H. pylori* and *L. pneumophila* ([@B14], [@B15], [@B17], [@B18]). It will be particularly interesting to study the role of this enzyme in the virulence of these organisms.

MATERIALS AND METHODS {#h3}
=====================

Ethics statement. {#h3.1}
-----------------

All work with animals was conducted according to the recommendations in the *Guide for the Care and Use of Laboratory Animals* ([@B47]). The protocol was approved by the Standing Committee on Animals of the Harvard Medical Area (protocol 04723).

Bacterial strains and plasmids. {#h3.2}
-------------------------------

*Francisella tularensis* LVS (kindly provided by Karen Elkins, U.S. Food and Drug Administration, Bethesda, MD) was grown in cysteine heart agar supplemented with 1% hemoglobin (CHAH) for 72 h at 37°C and 5% CO~2~, in modified Muller-Hinton broth (Becton, Dickinson, Franklin Lakes, NJ) supplemented with ferric pyrophosphate and IsoVitaleX (Becton, Dickinson, Franklin Lakes, NJ), or in tryptic soy broth (Difco, Detroit, MI). *Escherichia coli* strain DH5α was used for general cloning and was grown either in Luria-Bertani (LB) broth or on LB agar plates. When appropriate, ampicillin (100 µg/ml) and kanamycin (50 µg/ml) were added to broth medium, and kanamycin (10 µg/ml) was added to CHAH.

Construction of the *F*. *tularensis* LVS Δ*kdhAB* deletion mutant. {#h3.3}
-------------------------------------------------------------------

The Δ*kdhAB* mutant was constructed by allelic exchange ([@B48]) by a procedure described previously ([@B14]). The whole *kdhA* gene was deleted. As the last eight bases of *kdhA* overlap with *kdhB*, the first eight bases of *kdhB* were also deleted. The following primers were used: 5′-ACC[CCCGGG]{.ul}CACTTTCGTGCTTAGATATCT-3′ (XmaI site underlined) and 5′-TGT[GGTACC]{.ul}AGTTTTAAAAATTAAGTAAGT-3′ (KpnI site underlined) to amplify the 1-kb upstream region; 5′-ACC[GGTACC]{.ul}TAATTATAACCTTTTGACAAC-3′ (KpnI site underlined) and 5′-TGT[GAATTC]{.ul}GAAAGTAGGTGATATGATTGC-3′ (EcoRI site underlined) to amplify the 1-kb downstream region.

For complementation studies, plasmid p*kdhAB* encoding *kdhAB* genes under a *groEL* promoter was constructed. In brief, a DNA sequence containing open reading frames of both *kdhA* and *kdhB* genes was amplified by PCR with primers 5′-TG[GAATTC]{.ul}ATGAAACATAAACTAAAGCTAG-3′ (EcoRl site underlined) and 5′-TC[CTCGAG]{.ul}TTAGTAATATATAATCTTATCTT-3′ (Xhol site underlined). After restriction endonuclease digestion, the *kdhAB* DNA fragment was ligated into the EcoRI and XhoI sites of plasmid pTH17 ([@B49]).

Bacterial DNA/RNA preparation. {#h3.4}
------------------------------

Plasmids were introduced into *F. tularensis* LVS by electroporation, and miniplasmids for *E. coli* DH5α and *F. tularensis* LVS were prepared with a QIAprep spin miniprep kit according to the manufacturer's instructions (Qiagen, Venlo, Netherlands). Restriction enzymes and DNA-modifying enzymes were purchased from New England Biolabs. DNA ligations and transformations of chemically competent *E. coli* were performed by standard protocols ([@B50]).

LPS purification. {#h3.5}
-----------------

LPS was purified from *F. tularensis* WT and Δ*kdhAB* strains as described elsewhere ([@B49]). A modification of the hot phenol-water method was used ([@B51]).

Mouse infection and immunization studies. {#h3.6}
-----------------------------------------

Male BALB/cByJ, C57BL/6, TLR2^−/−^, and TLR4^−/−^ specific-pathogen-free mice (6 to 8 weeks old; Jackson Laboratory, Bar Harbor, ME) were housed in an animal facility at Harvard Medical School. All procedures conformed to protocols approved by the Institutional Animal Care and Use Committee. Bacterial virulence was assessed by intranasal challenge of BALB/cByJ mice (*n* = 6) with 10^3^ CFU of *F. tularensis* LVS bacteria or with 10^3^, 10^4^, or 10^5^ CFU of Δ*kdhAB* bacteria (inoculum volume, 50 µl per mouse). Mice were lightly anesthetized with isoflurane (Baxter, Deerfield, IL). The importance of the TLR2 signaling pathway in mouse survival after intranasal challenge with Δ*kdhAB* mutant bacteria (10^2^, 10^3^, or 10^4^ CFU) was assessed in C57BL/6 WT, TLR2^−/−^, and TLR4^−/−^ mice. In all these instances, survival was monitored over a 26-day period unless otherwise indicated.

For immunization studies, groups of BALB/cByJ mice (*n* = 10) were immunized by the intranasal route with three doses of bacteria at 2-week intervals; the doses were 10, 10, and 10^2^ CFU for *F. tularensis* LVS and 10^3^, 10^4^, and 10^5^ CFU for the Δ*kdhAB* mutant. A mock immunization group that received PBS served as a control. Four weeks after the last dose, mice were challenged intranasally with either 10^4^ CFU of LVS (10 × LD~50~) or 10 CFU of strain Schu S4 (10 × LD~50~). Mice were challenged with the *F. tularensis* Schu S4 strain at the animal biosafety level 3 (ABSL3) core facility at Harvard Medical School. Titers of serum antibody to LPS were measured by ELISA as described previously ([@B26]).

Organ bacterial burden and histopathology. {#h3.7}
------------------------------------------

BALB/cByJ mice were challenged intranasally with 10^3^ CFU of *F. tularensis* LVS or Δ*kdhAB* bacteria. Six days after infection, mice were killed, blood was collected, and tissues were weighed, hand mashed, and homogenized with a Stomacher 80-paddle action blender (Seward, Port Saint Lucie, FL). Serial 10-fold dilutions were prepared with sterile 1× PBS supplemented with 2% fetal bovine serum. A 10-µl volume of each dilution was plated onto CHAH plates and incubated at 37°C in 5% CO~2~ until colonies became visible (\~72 h). Data were expressed as CFU per gram of tissue or per milliliter of blood.

Histological analysis was performed on the livers of *F. tularensis* Schu S4-challenged mice that had been immunized with *F. tularensis* LVS or ∆*kdhAB* mutant or had been given PBS as a control. Livers from each group of mice were fixed in 10% formalin solution, embedded in paraffin, and stained with hematoxylin and eosin after sectioning.

Bronchoalveolar lavage. {#h3.8}
-----------------------

BALB/cByJ mice were challenged intranasally with 10^3^ CFU of *F. tularensis* LVS or Δ*kdhAB* bacteria. After 24 h, the mice were killed, the tracheae were exposed, and the lungs were lavaged with 0.5 ml of PBS supplemented with 0.5 mM EDTA. TNF-α and IL-1β were assayed with ELISA Duoset kits (R&D Systems, Minneapolis, MN).

BMM infection and measurements of cytokine production and gene expression. {#h3.9}
--------------------------------------------------------------------------

Bone marrow was flushed with PBS from the femurs of C57BL/6J mice (6 to 8 weeks old; Jackson Laboratory), spun down, resuspended in BMM growth medium (Dulbecco modified Eagle medium \[DMEM\] containing [d]{.smallcaps}-glucose \[4.5 mg/liter\], [l]{.smallcaps}-glutamine \[4 mM\], and sodium pyruvate \[110 mg/liter\] \[Invitrogen, Carlsbad, CA\] supplemented with 10% heat-inactivated fetal bovine serum \[FBS\] \[Invitrogen\] and 30% cell line L929-conditioned DMEM with nonessential amino acids). The cells from each femur were plated in two deep petri dishes, and the plates were incubated at 37°C in 5% CO~2~ in the presence of gentamicin (50 µg/ml). After 3 days, BMM growth medium was added to petri dishes. The cells were incubated for an additional 2 to 3 days.

For measurements of cytokine release, BMMs were seeded in 24-well plates at a density of 5 × 10^5^ cells/well, and the plates were incubated at 37°C in 5% CO~2~ overnight. The macrophages were then infected with mid-logarithmic-phase *F. tularensis* LVS or Δ*kdhAB* bacteria at an MOI of 10, 20, or 50 (ratio of bacteria to macrophages) for 24 h. TNF-α and IL-1β in cell supernatants were measured with ELISA Duoset kits according to the manufacturer's recommendations (R&D Systems).

For measurements of gene expression, BMMs were seeded in 6-well plates at a density of 2 × 10^6^ cells/well, and the plates were incubated at 37°C in 5% CO~2~ overnight. The macrophages were then infected with mid-log *F. tularensis* LVS or Δ*kdhAB* bacteria at an MOI of 10. At various time points, cells were lysed in 0.4 ml TRIzol (Invitrogen), and RNA was isolated according to the manufacturer's instructions. Reverse transcription was performed with a qScript Flex cDNA synthesis kit (Quanta Biosciences, Gaithersburg, MD) according to the manufacturer's instructions. Real-time PCR was conducted with Perfecta SYBR green supermix (Quanta Biosciences) in a Bio-Rad iCycler iQ system (45 cycles, with 1 cycle consisting of 15 s at 95°C, 45 s at 60°C, and 30 s at 72°C). Gene expression was normalized to the expression of the RNA polymerase II (RP II) gene, which is considered a stably expressed housekeeping gene ([@B52]). The following primer sets were used: for TNF-α, sense (5′-TATGGCTCAGGGTCCAACTC-3′) and antisense (5′-CTCCCTTTGCAGAACTCAGG-3′); for IL-1β, sense (5′-GGGCCTCAAAGGAAAGAATC-3′) and antisense (5′-TACCAGTTGGGGAACTCTGC-3′); and for RP II, sense (5′-GCACCACGTCCAATGATAT-3′) and antisense (5′-CTGGCGGTTGACCCCATGAC-3′). Relative gene expression was calculated by the ∆∆*C*~*T*~ method ([@B53]) and reported as fold induction over the uninfected control level (mean ± standard deviation \[SD\] values for samples from three independent experiments).

Murine macrophage-like cell line infection. {#h3.10}
-------------------------------------------

WT, Unc93B^−/−^, MyD88^−/−^, TLR4^−/−^, and TLR2^−/−^ murine macrophage-like cell lines, kindly provided by Douglas T. Golenbock (University of Massachusetts Medical School, Worcester, MA), were seeded in 24-well plates at a density of 5 × 10^5^ cells/well, and the plates were incubated overnight at 37°C in 5% CO~2~. The macrophages were then infected with mid-log *F. tularensis* LVS or Δ*kdhAB* bacteria at an MOI of 100. After 2 h, cells were washed three times with Dulbecco's PBS and lysed in 60 µl of lysis buffer (kit BF14100; R&D Systems). IL-1β in lysates was measured with an ELISA Duoset kit (R&D Systems).

NF-κB reporter luciferase assay. {#h3.11}
--------------------------------

Stable HEK293 cell lines expressing TLR2 receptor were kindly provided by Douglas T. Golenbock. HEK-TLR2 and HEK-TLR4/MD2 cells were seeded into 12-well tissue culture plates at a density of 3 × 10^5^ cells/well. The following day, cells were transiently transfected with luciferase reporter genes; Genejuice (EMD Chemicals, Darmstadt, Germany) was used per the manufacturer's recommendations. To assess NF-κB activation, an NF-κB luciferase reporter gene (consisting of an artificial promoter NF-κB site driving the firefly luciferase gene) was cotransfected with a constitutively active *Renilla* luciferase reporter gene, phRL-TK (Promega, Fitchburg, WI); phRL-TK was used to normalize transfection efficiency. The following day, the cells were stimulated as indicated in Results. During stimulation with LPSs from *F. tularensis* LVS or Δ*kdhAB* bacteria, the mixture contained soluble CD14 recombinant protein (5 µg/ml) (ProSci Inc., Poway, CA). After 24 h of stimulation, the cells were lysed in passive lysis buffer (Promega), and reporter gene activity was measured with a plate reader luminometer (Victor2; PerkinElmer Life Sciences) and the Dual-Luciferase reporter assay system (Promega).

Surface antigen-binding assay. {#h3.12}
------------------------------

Evaluation of FopA antibody binding to the bacterial surface was performed as described previously ([@B24]), with some modifications. In brief, cultures of WT *F. tularensis* LVS, ∆*kdhAB*, and ∆*wbtA* bacteria were grown overnight in brain heart infusion (BHI) broth. Cultures were diluted in fresh BHI medium to an optical density at 620 nm (OD~620~) of 0.07, and bacteria were further grown to an OD~620~ of 0.5. After the bacteria were harvested, 6 × 10^8^ bacteria from each strain (in a 50-µl volume) were mixed with monoclonal FopA antibodies (final concentration, 0.1 mg/ml) ([@B54]) in PBS containing 0.1% glucose and 0.5% bovine serum albumin (BSA). After incubation for 1 h at 37°C, bacteria were washed three times with PBS containing 0.1% glucose. After the final wash, pellets were resuspended in Laemmli sample buffer (Bio-Rad, Hercules, CA). Protein samples were resolved on 5 to 20% Protean TGX gels (Bio-Rad) and transferred to nitrocellulose membranes. Alkaline phosphatase (AP)-conjugated rabbit anti-mouse antibody (Abcam, Cambridge, MA) was used to detect heavy- and light-chain subunits of bound FopA antibodies.

LPS analysis by SDS-PAGE and MALDI-TOF mass spectrometry. {#h3.13}
---------------------------------------------------------

Outer membranes from *F. tularensis* LVS and Δ*kdhAB* bacteria were isolated, resolved by Tricine SDS-PAGE, and stained with zinc as previously described ([@B14]). Lipid A from LVS and Δ*kdhAB* bacteria was isolated and analyzed by negative-ion matrix-assisted laser desorption ionization−time of flight (MALDI-TOF) mass spectrometry ([@B14]).

Data analysis. {#h3.14}
--------------

Data are expressed as mean ± standard deviation (SD) values. Unpaired Student's *t* test was used for statistical analysis. A *P* value of \<0.05 was considered significant.

SUPPLEMENTAL MATERIAL {#h4}
=====================
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The *F. tularensis* Δ*kdhAB* mutant strain and parental LVS show similar growth behavior in broth and macrophages and similar serum sensitivity. (A) J774A.1 and MH-S macrophage-like cell lines were seeded in 24-well plates at a density of 2 × 10^5^ cells/well overnight and infected with WT LVS or Δ*kdhAB* bacteria (MOI = 100) for 2 h. The cells were then washed three times with Dulbecco's PBS (DPBS), treated with gentamicin (100 µg/ml) in macrophage growth medium for 1 h, and incubated in macrophage growth medium. At the time of gentamicin treatment and 24 and 48 h afterward, cells were lysed with 1% saponin (in DPBS), serial dilutions of lysate were plated onto CHAH, and CFU were counted (mean ± SD; *n* = 2). (B) Growth curves of WT LVS and Δ*kdhAB* bacteria in Muller-Hinton (MH) broth. (C) Bacteria were grown to mid-logarithmic phase, washed, and resuspended in DPBS. Heat-inactivated 10% normal rabbit serum (Lampire Biological Laboratories, Pipersville, PA) was added to the bacteria. Heat-inactivated complement (65°C for 30 min) or active baby rabbit complement (Cedarlane Laboratories) was added at a 1:10 dilution. The number of bacteria before and 30 min after the addition of complement was measured by plating onto CHAH. *F. tularensis* Δ*wzy* mutant strain, which produces a rough LPS ([@B45]), served as a positive control for complement killing activity. Download
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Figure S1, EPS file, 0.8 MB
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Purified *F. tularensis* LPS does not induce macrophages. Various concentrations of purified LPS from *F. tularensis* LVS and ∆*kdhAB* mutant were incubated with BMMs for 24 h. BMM culture supernatants were tested for release of TNF-α and IL-1β by ELISA (B&D Biosystems). To induce IL-1β secretion after 24-h incubation, BMMs were further incubated with 5 mM ATP for 1 h. *E. coli* LPS induction of macrophages is shown as a positive control. Download
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Figure S2, JPG file, 0.5 MB
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*F. tularensis* ∆*kdhAB* mutant bacteria do not release any component that induces macrophages. *F. tularensis* LVS and ∆*kdhAB* bacterial culture supernatants were collected and filtered. After concentration of the supernatants with a Centricon filter device (EMD Millipore, Billerica, MA), samples were mixed with macrophage growth medium (1:10 dilution) and incubated with BMMs for 24 h. (A and B) BMM culture supernatants were tested for release of TNF-α (A) and IL-6 (B) by ELISA (B&D Biosystems). *E. coli* LPS and PAM~3~CSK~4~ induction of macrophages are shown as positive controls. Download
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Figure S3, JPG file, 0.5 MB
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Monosaccharide composition of LVS and Δ*kdhAB* core oligosaccharides, determined by high-performance anion-exchange chromatography as previously described ([@B14])
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Table S1, DOCX file, 0.1 MB.
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